Specialty Pharmacy

Top news of the day from across the health care landscape.

Study evaluates when and how the increased risk of autoimmune thyroid disease develops in patients diagnosed with rheumatoid arthritis.

Bijuva (estradiol and progesterone) is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.

Biosimilars adalimumab and etanercept showed equivalent safety and efficacy to reference products in patients with rheumatoid arthritis.

New data show a survival benefit with pembrolizumab (Keytruda) as both a monotherapy and combination treatment with chemotherapy.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses how collaboration with manufacturers can help specialty pharmacies prepare from a patient services and distribution perspective.

Top news of the day from across the health care landscape.

Officials with the FDA have approved Jazz Pharmaceuticals' Xyrem (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness in pediatric patients aged 7 to 17 years with narcolepsy.

Hepatitis C virus found to increase mortality in individuals coinfected with HIV, however, treatment with direct-acting antivirals may reduce harm.

Tildrakizumab-asmn (Ilumya) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Phase 3 data show combination therapy demonstrates clinical benefit as first-line treatment.

A look at last week's top stories in the world of pharmacy.

Amgen will make evolocumab (Repatha) available at a list price of $5850, a 60% reduction from its annual list price of $14,100.

New analysis examines the role of the HIV/AIDS epidemic in cancer survival rates among adolescents and young adults.

Coinfection with HIV and tuberculosis may affect drug-related adverse events, hospital readmissions, and treatment duration.

Top news of the day from across the health care landscape.

Patients with rheumatoid arthritis who achieve low disease activity or remission may successfully taper their biologic disease-modifying antirheumatic drugs, saving costs as a result.

Study explores the effect of microglia dysregulation on progression of neurodegeneration in disorders such as Alzheimer disease and amyotrophic lateral sclerosis.

The approval marks the first new antiviral flu treatment with a novel mechanism of action backed by the agency in nearly 20 years.

Mobile technology has helped to facilitate communication between pharmacists, patients, and their caregivers.

Study compares 2-year survival between patients with metastatic non-small cell lung cancer treated at academic and community centers.

Certain environmental conditions, such as salinity and temperature, may incite structural changes in myelin sheaths.

Top news of the day from across the health care landscape.

Australia on track to achieve World Health Organization targets for eliminating hepatitis C virus over the next 10 to 15 years.

A post hoc analysis of clinical trial data showed oral ozanimod improved cognitive processing speed and reduced annualized relapse rates and MRI lesions in multiple sclerosis.

Dolutegravir plus lamivudine showed non-inferiority to a 3-drug, first-line regimen in treating HIV infection.

Top news of the day from across the health care landscape.

The first study to evaluate population-level roll-out of pre-exposure prophylaxis (PrEP) for HIV in men who have sex with men has demonstrated rapid decline of new HIV infections.